Navigation Links
Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)

LA JOLLA, Calif., April 25 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), a biotechnology company developing medical products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that the Company's management and clinical and regulatory consultants met on April 16 with members of the United States Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. The purpose of the meeting was to discuss the appropriate regulatory pathway for filing a marketing application of ATPace(TM) as an antiarrhythmic drug for the acute termination of paroxysmal supraventricular tachycardia (PSVT).

Based on discussions held during the meeting and prior written communications between Duska and the FDA, the Company believes that the FDA would consider a New Drug Application (NDA) under section 505(b)(2) for ATPace(TM) subject to additional clinical data to be furnished by the Company. The 505(b)(2) NDA relies in part upon relevant published data obtained by entities other than the Company.

Dr. James Kuo, Duska's Chairman and CEO, said, "I am pleased to report that this meeting with the FDA was both positive and constructive. Together with our CRO, Cato Research, Inc., we have already commenced activities aimed at the generation of the supplemental data requested by the FDA. The 505(b)(2) NDA filing provides an expedited route for potential approval of ATPace(TM)," he added.

Dr. Amir Pelleg, Duska's President and Chief Scientific Officer, stated, "It has been our goal to commercialize the first ATP-based drug in the United States and I believe we are now much closer to attaining that goal as a result of this meeting. Formulations of ATP, which is the active ingredient in ATPace(TM), have been used for over 50 years in Europe in the treatment of PSVT. I am confident that our drug would manifest a safety and efficacy profile similar to that of the European formulations."

About ATPace(TM)

ATPace(TM) is Duska's investigational intravenous pharmaceutical formulation of ATP for the acute treatment of paroxysmal supraventricular tachycardia (PSVT). The bradycardic (heart rate slowing) effect of ATP, in particular its transient blockade of atrio-ventricular nodal conduction, has been shown in multiple published clinical studies to terminate re-entrant PSVT involving the atrio-ventricular node.

About PSVT

PSVT (paroxysmal supraventricular tachycardia) is a rapid regular heart rate originating in the atria. It has been estimated that there are 89,000 new cases per year in the United States alone. PSVT is one of the most common cardiac arrhythmias.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., based in La Jolla, California, is an emerging biotechnology company that is focused on the development of therapeutic, medical device and diagnostic products related to adenosine 5'-triphosphate (ATP) and cell-surface P2 receptors (P2R). Duska owns or has exclusive license rights to a number of proprietary products, four of which are currently in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, enhancement of sperm motility, treatment of chronic obstructive pulmonary disorder, and mitigation of the toxic effects of radiation exposure. For more information, visit Duska's website at

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that the Company believes that the FDA would consider a New Drug Application (NDA) under section 505(b)(2) for ATPace(TM) subject to additional clinical data to be furnished by the Company. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
2. CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
3. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
4. Hyperion Therapeutics Elects Lota Zoth to Board of Directors
5. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
6. Antisense therapeutics scientist out to pull more big deals
7. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
8. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
9. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
10. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
11. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology: